Listar DAAPC-Artículos, capítulos... por autor "cb0b2df8-45f4-4694-b450-df665316792f"

Mostrando ítems 1-8 de 8

    • Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 

      Aurilio, Gaetano; Cimadamore, Alessia; Mazzucchelli, Roberta; López-Beltrán, Antonio; Verri, Elena; Scarpelli, Marina; Massari, Francesco; Cheng, Liang; Santoni, Matteo; Montironi, Rodolfo (MDPI, 2020)
      Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is ...

    • Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy 

      Cimadamore, Alessia; Gasparrini, Silvia; Massari, Francesco; Santoni, Matteo; Cheng, Liang; López-Beltrán, Antonio; Scarpelli, Marina; Montironi, Rodolfo (MDPI, 2019)
      Liquid biopsy, based on the circulating tumor cells (CTCs) and cell-free nucleic acids has potential applications at multiple points throughout the natural course of cancer, from diagnosis to follow-up. The advantages of ...

    • Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer 

      López-Beltrán, Antonio; Cimadamore, Alessia; Blanca, Ana; Massari, Francesco; Vau, Nuno; Scarpelli, Marina; Cheng, Liang; Montironi, Rodolfo (MDPI, 2021)
      A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the ...

    • New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 

      Aurilio, Gaetano; Cimadamore, Alessia; Santoni, Matteo; Nolé, Franco; Scarpelli, Marina; Massari, Francesco; López-Beltrán, Antonio; Cheng, Liang; Montironi, Rodolfo (MDPI, 2020)
      Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in ...

    • Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 

      Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Scarpelli, Marina; Montironi, Rodolfo; Massari, Francesco (Frontiers, 2018)
      Management of localized and advanced prostate cancer benefits from several therapeutic options with a surprising improvement in terms of clinical outcome. The selection of patients more likely to benefit from a specific ...

    • Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor 

      Mollica, Veronica; Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Scarpelli, Marina; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Battelli, Nicola; Montironi, Rodolfo; Massari, Francesco (MDPI, 2019)
      The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with ...

    • The Human Microbiota and Prostate Cancer: Friend or Foe? 

      Massari, Francesco; Mollica, Veronica; Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Scarpelli, Marina; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Battelli, Nicola; Montinori, Rodolfo; Brandi, Giovanni (MDPI, 2019)
      The human microbiome is gaining increasing attention in the medical community, as knowledge on its role not only in health but also in disease development and response to therapies is expanding. Furthermore, the connection ...

    • Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer 

      Cimadamore, Alessia; Aurilio, Gaetano; Nolé, Franco; Massari, Francesco; Scarpelli, Marina; Santoni, Matteo; López-Beltrán, Antonio; Cheng, Liang; Montironi, Rodolfo (MDPI, 2020)
      Current developments in the treatment of genitourinary tumors underline the unmet clinical need for biomarkers to improve decision-making in a challenging clinical setting. The detection of circulating tumor cells (CTCs) ...